Picking out the future's biggest business winners in a crowded startup space isn't easy, but Sequoia Capital has been able to spot tech darlings such as Airbnb, Stripe, Instacart, and Dropbox. Bryan Schreier, Partner at Sequoia, was with us to give us the hottest trends in VC. Schreier identified the common trait that these best-of-breed companies embody. He said these companies are going after "greenfield market opportunities" that tend to be new or ripe for disruption. The venture capitalist is excited about the potential of virtual reality. He is also taking a look at a lot of cryptocurrency opportunities. Although still in the early days, Schreier said cryptocurrency technology reminds him of the beginning stages of the internet. Scheier says that he sees real estate as one of the industries ready to be disrupted by blockchain.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More